Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
A useful tool, but not in every case
July 17, 2013
By: Michael A.
Director, Fairmount Partners
Many CRO employees are critical of a common methodology that private equity firms employ to finance their acquisitions, i. e. the use of debt. Typically, a private equity firm buying a publicly owned company uses the cash contributed by the partners in one of its funds for approximately half of the money it pays shareholders. It borrows the rest, using as collateral the assets and overall creditworthiness of the company it’s buying. Private equity managers are hardly the only class of financial professionals who regard the use of financial leverage as an appropriate tool to help finance an acquisition. But CRO managers who have not had an extensive financial education might view the imposition of debt on a service business as unwise. Indeed, some with whom we have discussed this issue view the imposition of financial leverage as a major constraint on management’s ability to continue increasing revenue and profits. After all, as many outsourcing firms’ employees have pointed out to me, a CRO is a service business and its employees are its most productive assets. While many firms have small laboratory divisions, they have fixed asset bases made up largely of office buildings, not extensive campuses of laboratories, vivariums, and manufacturing facilities. It doesn’t seem to make sense to use debt as an important element of a service business’s capital structure. Historically, most publicly held CROs have used modest amounts of long term debt. SEC filings for the quarter ended March 31, 2013 show the following data:
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !